Heska (NASDAQ:HSKA) Coverage Initiated at Piper Jaffray Companies

Share on StockTwits

Investment analysts at Piper Jaffray Companies began coverage on shares of Heska (NASDAQ:HSKA) in a report issued on Wednesday, MarketBeat reports. The brokerage set a “neutral” rating and a $68.00 price target on the medical research company’s stock. Piper Jaffray Companies’ price objective points to a potential downside of 4.80% from the company’s current price.

A number of other equities research analysts have also recently commented on the stock. ValuEngine raised shares of Heska from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. BidaskClub raised shares of Heska from a “sell” rating to a “hold” rating in a report on Wednesday. Canaccord Genuity reduced their target price on shares of Heska from $95.00 to $75.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Finally, Guggenheim started coverage on shares of Heska in a report on Thursday, May 23rd. They issued a “neutral” rating for the company. One analyst has rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Heska has an average rating of “Hold” and an average target price of $85.25.

Shares of NASDAQ:HSKA opened at $71.43 on Wednesday. The company has a 50-day simple moving average of $72.22 and a 200-day simple moving average of $77.45. Heska has a one year low of $62.47 and a one year high of $114.50. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.05 and a current ratio of 3.93. The stock has a market capitalization of $538.90 million, a price-to-earnings ratio of 50.30 and a beta of 1.07.

Heska (NASDAQ:HSKA) last announced its earnings results on Tuesday, August 6th. The medical research company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. Heska had a net margin of 1.93% and a return on equity of 6.35%. The business had revenue of $28.15 million during the quarter, compared to analysts’ expectations of $29.19 million. As a group, research analysts forecast that Heska will post 0.05 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. Granite Investment Partners LLC acquired a new position in shares of Heska during the first quarter worth about $13,897,000. Grandeur Peak Global Advisors LLC acquired a new position in shares of Heska during the second quarter worth about $6,362,000. Nine Ten Capital Management LLC acquired a new position in shares of Heska during the second quarter worth about $3,728,000. Nuveen Asset Management LLC acquired a new position in shares of Heska during the second quarter worth about $3,221,000. Finally, Redmile Group LLC increased its stake in shares of Heska by 14.3% during the first quarter. Redmile Group LLC now owns 226,013 shares of the medical research company’s stock worth $19,238,000 after acquiring an additional 28,300 shares during the period. 89.02% of the stock is owned by institutional investors and hedge funds.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Further Reading: How analysts view the yield curve

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Amgen  Receives New Coverage from Analysts at Sanford C. Bernstein
Amgen Receives New Coverage from Analysts at Sanford C. Bernstein
Boc Hong Kong  Upgraded at Goldman Sachs Group
Boc Hong Kong Upgraded at Goldman Sachs Group
HSBC  Receives Underweight Rating from JPMorgan Chase & Co.
HSBC Receives Underweight Rating from JPMorgan Chase & Co.
Cognizant Technology Solutions  Given New $69.00 Price Target at Citigroup
Cognizant Technology Solutions Given New $69.00 Price Target at Citigroup
ShowHand Price Up 12.6% Over Last 7 Days
ShowHand Price Up 12.6% Over Last 7 Days
MIR COIN  Trading Up 82.3% Over Last Week
MIR COIN Trading Up 82.3% Over Last Week


© 2006-2019 Ticker Report